George D Hartman

USPTO Granted Patents = 183 (Patent Applications = 10)

CIPO Patents = 1 (Patent Applications = 12)

EPO Patents = 9 (Patent Applications = 12)

Average Co-Inventor Count = 2.4

ph-index = 25

Forward Citations = 2,166(Granted Patents)

Forward Citations (Not Self Cited) = 1,866(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Plainsboro, NJ (US) (1977)
Radnor, PA (US) (2014)
Landsdale, PA (US) (1994 - 2017)
Doylestown, PA (US) (2015 - 2017)
Lansdale, PA (US) (1978 - 2023)

Company Filing History:

Novira Therapeutics, Inc.

Merck Sharp + Dohme Corp.

patents

5. 2 out of 60

Janssen Sciences Ireland Unlimited Company

where one patent can have more than one assignee

Years Active: 1977-2025

Loading Chart...

Areas of Expertise:

Nlrp3 Inflammasome Inhibitors

Hepatitis B Treatments

Capsid Assembly Inhibitors

Azepane Derivatives

Piperidine Derivatives

Mitotic Kinesin Inhibitors

Antiviral Agents

Oxadiazepinone Derivatives

Combination Therapy

Prodrugs

Crystalline Forms

Heteroaryl Inhibitors

183 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12435043 - Inhibitors of NLRP3 inflammasome (2025-10-07),

2. 12421196 - Inhibitors of NLRP3 inflammasome (2025-09-23),

3. 12215087 - Inhibitors of NLRP3 inflammasome (2025-02-04),

4. 12129251 - N-oxide inhibitors of NLRP3 inflammasome (2024-10-29),

5. 11787805 - N-oxide inhibitors of NLRP3 inflammasome (2023-10-17),

6. 11708334 - Inhibitors of NLRP3 inflammasome (2023-07-25),

7. 11702391 - Inhibitors of NLRP3 inflammasome (2023-07-18),

8. 11129834 - Combinations and methods comprising a capsid assembly inhibitor (2021-09-28),

9. 10987359 - Oxadiazepinone derivatives and methods of treating hepatitis B infections (2021-04-27),

10. 10975077 - Diazepinone derivatives and their use in the treatment of hepatitis B infections (2021-04-13),

11. 10632112 - Combination therapy for treatment of HBV infections (2020-04-28),

12. 10556904 - Derivatives and methods of treating hepatitis B infections (2020-02-11),

13. 10544141 - Derivatives and methods of treating hepatitis B infections (2020-01-28),

14. 10538519 - Derivatives and methods of treating hepatitis B infections (2020-01-21),

15. 10537580 - Azocane and azonane derivatives and methods of treating hepatitis B infections (2020-01-21),

Title: Innovator Spotlight: George D Hartman

Introduction: Meet the prolific inventor George D Hartman, hailing from Lansdale, PA (US), with an impressive portfolio of 179 patents in his name. His groundbreaking work in the field of pharmaceuticals and treating age-related disorders has put him at the forefront of innovation.

Latest Patents: Among his latest patents, George D Hartman has developed groundbreaking compounds that act as inhibitors of NLRP3 inflammasomes, showcasing his commitment to addressing inflammation-related disorders, inflammaging, and age-related diseases such as hearing loss. The pharmaceutical compositions he has formulated have the potential to revolutionize treatment methods for these conditions.

Career Highlights: George D Hartman has made significant contributions to the field of pharmaceuticals through his tenure at renowned companies such as Merck & Company, Inc. and Novira Therapeutics, Inc. His innovative approach to drug development and his relentless pursuit of scientific advancements have established him as a respected figure in the industry.

Collaborations: Throughout his career, George D Hartman has collaborated with esteemed colleagues such as Mark E Duggan and Wasyl Halczenko. The synergy between these visionaries has led to the successful development of cutting-edge pharmaceutical solutions, further solidifying George D Hartman's reputation as a pioneer in the field.

Conclusion: In conclusion, George D Hartman's exceptional track record of patenting novel inventions underscores his unwavering dedication to advancing pharmaceutical research and improving the lives of individuals affected by inflammation-related disorders and age-related diseases. His innovative spirit and collaborative efforts continue to inspire advancements in the healthcare industry.

This text is generated by artificial intelligence and may not be accurate.